The acute effects of chemotherapy upon the oral cavity: Prevention and management

Turkish Journal of Cancer

Volumn 31, Issue 3, 2001, Pages 93-105

  Ilgenli, Tunç ^a   Ören, Hale ^b   Uysal, Kamer ^b  

^a EGE UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Hemorrhage; Infection; Mucositis; Oral care; Oral complications; Xerostomia

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMPHOTERICIN B; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BETA CAROTENE; BETA LACTAM ANTIBIOTIC; CLOTRIMAZOLE; CYTOKINE; DIURETIC AGENT; ETOPOSIDE; FLUCONAZOLE; FLUOROURACIL; FOLINIC ACID; FOSCARNET; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 11; METHOTREXATE; NYSTATIN; OPIATE; PROPANTHELINE BROMIDE; SEDATIVE AGENT; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG INDUCED DISEASE; HUMAN; IMMUNE DEFICIENCY; MOUTH DISEASE; MOUTH HYGIENE; MOUTH INFECTION; MUCOSA INFLAMMATION; NEUROPATHY; NUTRITIONAL DISORDER; PAIN; PARESTHESIA; RADIATION INJURY; XEROSTOMIA;

EID: 0034758661     PISSN: 10193103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Oral complications of cancer therapy
2. Oral complications associated with cancer therapy. An M.D. Anderson Cancer Center experience
3. Oral health care for the cancer patient
4. High dose chemotherapy regimens
5. Oral manifestations of systemic chemotherapy and their management
6. Oral complications of cancer chemotherapy: Present status and future studies
7. Mucositis
8. Oral toxicity
9. Clinicopathologic effects of cancer chemotherapeutic agents on human buccal mucosa
10. Alterations in the oral mucosa caused by chemotherapeutic agents
11. Mucosal alterations
12. Hematologic effects of chemotherapy
13. Chemotherapy-associated oral mucosal lesions in patients with leukaemia or lymphoma
14. Prevention and management of oral mucositis induced by antineoplastic therapy
15. Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity
16. Prevention and treatment of oral mucositis following cancer chemotherapy
17. Assessment and management of chemotherapy-induced mucositis in children
18. Oral toxicity of chemotherapeutic agents
19. Consensus Development Conference on Oral Complications of Cancer Therapies: Diagnosis, prevention, and treatment
20. The incidence of oral complications in pediatric patients receiving high dose chemotherapy
21. Oral complications of local and systemic cancer treatment
22. Chemotherapy associated oral mucosal lesions in patients with leukemia or lymphoma
23. Oral care for the cancer patient
24. Scoring oral mucositis
25. Comparison of methods to determine the prevalence and nature of oral mucositis
26. Management of oral mucositis during local radiation and systemic chemotherapy: A study of 98 patients
27. Oral complications of cancer therapies. Oral complications in the pediatric population
28. Oral complications in pediatric oncology patients
29. New frontiers in the management of chemotherapy-induced mucositis
30. Dental oncology: The management of disease and treatment related oral/dental complications associated with chemotherapy
31. Oral complications of chemotherapy and their management
32. The role of surveillance cultures in patients likely to develop chemotherapy-induced mucositis
33. Effect of intravenous hyperalimentation and oral care on the development of oral stomatitis during cancer chemotherapy
34. Oral cavity complications of bone marrow transplantation
35. Causes of death in cancer patients
36. Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy
37. Comparison of the plaque microflora in immunodeficient and immunocompetent dental patients
38. Microbiology of acute periodontal infection in myelosuppressed cancer patients
39. Effect of granulocytopenia on oral microbial relationships in patients with acute leukemia
40. Viridans streptococcal bacteremia in patients with hematological and solid malignancies
41. Gram-negative enteric bacteria in the oral cavity of leukemia patients
42. Streptococcus salivarias sepsis in children with malignancies
43. Infection in the patient receiving chemotherapy for cancer: Oral considerations
44. Septicemia in pediatric oncology patients: The significance of viridans streptococcal infections
45. Oral complications of myeloproliferative diseases
46. Current approaches to the management of fungal infections in cancer patients
47. The detection of oral candida in pediatric leukemia patients
48. Impact of the changing epidemiology of fungal infections in the 1990's
49. Comparative trial of oral clotrimazole and nystatin for oropharyngeal candidiasis: Prophylactic use in orthotopic liver transplant patients
50. Candidiasis in the transplant patient
51. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
52. Management of fever in patients with cancer and treatment-induced neutropenia
53. Oral complications of bone marrow transplantation
54. Oral acyclovir prophylactic treatment of herpes simplex virus infections after bone marrow transplantation
55. Infections in patient with cancer: Overview and epidemiology
56. Recurrent infection with herpes simplex virus after marrow transplantation: Role of specific immune response and acyclovir treatment
57. Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis
58. Effect of acyclovir on radiation and chemotherapy induced mouth lesions
59. Prophylaxis of herpes simplex virus infections after bone marrow transplantation of oral acyclovir
60. Acyclovir prophylaxis of herpes virus infections in severely immunocompromised patients: A randomised double-blind trial
61. Antineoplastic agents and their oral manifestations
62. Abnormalities in platelet function in the myeloproliferative disorders
63. Hematologic parameters as predictors of oral involvement in the presentation of acute leukemia
64. The effects of radiation on the developing dentition and supporting bone
65. The symptom experience of mucositis, stomatitis, and xerostomia
66. Salivary secretion rate, yeast cells, and oral candidiasis in patients with acute leukemia
67. Iatrogenic causes of salivary gland dysfunction
68. Options for artificial nutrition of cancer patients
69. Nutritional support in children undergoing bone marrow transplantation
70. Life threatening complications of high dose chemotherapy
71. The value of parenteral nutrition support. Chemotherapy and radiation treatment
72. An oral disease prevention program for patients receiving radiation and chemotherapy
73. Inhibition of 5-fluorouracil-induced mucositis by oral cryotherapy
74. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis
75. Allopurinol mouthwash and 5-fluorouracil-induced oral toxicity
76. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis
77. Propantheline prevention of mucositis from etoposide
78. High dose methotrexate: A critical reappraisal
79. The modifying effects of beta-carotene on radiation and chemotherapy induced oral mucositis
80. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy
81. Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis
82. Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients
83. Interleukin-1 increases thymidine labelling index of normal tissue of mice but not the tumor
84. Alteration in the frequency, severity, and duration of chemotherapy-induced mucositis in hamsters by interleukin-11
85. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor β-3
86. Effect of oral glutamine supplementation during bone marrow transplantation
87. Prostaglandin E2 for prophylaxis of oral mucositis following BMT
88. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population
89. Chlorhexidine prophylaxis for chemotherapy and radiotherapy induced stomatitis: A randomized double-blind trial
90. Oropharyngeal mucositis complicating bone marrow transplantation: Prognostic factors and the effect of chlorhexidine mouth rinse
91. Effect of chlorhexidine rinsing on the orapharyngeal ecology in patients with head and neck cancer who have irradiation mucositis
92. Control of oral mucositis and candidiasis in marrow transplantation: A prospective, double-blind trial of chlorhexidine digluconate oral rinse
93. Therapeutic use of chlorhexidine in bone marrow transplant patients: Case studies
94. Oral complications of acute leukemia: Prophylactic impact of chlorhexidine mouth rinse regimen
95. Expanded and future uses of mouth rinses
96. Effects of chlorhexidine during immunosuppressive chemotherapy. A preliminary report
97. Mucositis prevention by selective elimination of oral flora in irradiated head and neck cancer patients
98. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis
99. The therapeutic management of radiogenic oral mucositis
100. Management of mucositis in oral irradiation
101. Performance of a hydroxy propyl-cellulose film former in normal and ulcerated oral mucosa
102. Clinical evaluation of MGI 209, an anesthetic film-forming agent for relief from painful oral ulcers associated with chemotherapy